Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis. Recent newsflow reflects heightened clinical activity for the candidate as it progresses through the US-based Phase Ib/II NEXICART-2 clinical trial. Notab
04 Apr 2025
All eyes on NEXICART-2
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
All eyes on NEXICART-2
Immix Biopharma, Inc. (IMMX:NAS) | 0 0 0.0%
- Published:
04 Apr 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
8 -
Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis. Recent newsflow reflects heightened clinical activity for the candidate as it progresses through the US-based Phase Ib/II NEXICART-2 clinical trial. Notab